Amgen to acquire American biopharma company ChemoCentryx for $3.7bn
Amgen has agreed to acquire ChemoCentryx, a biopharma company engaged in developing medications for inflammatory and autoimmune diseases and cancer, in an all-cash deal worth ... Read More
AstraZeneca to acquire US biotech firm TeneoTwo for up to $1.27bn
UK-based pharma giant AstraZeneca has signed a deal worth up to $1.27 billion to acquire American biotech company TeneoTwo in a move to bolster its ... Read More
Isleworth Healthcare scraps $602m merger deal with biopharma firm Cytovia
Isleworth Healthcare Acquisition Corporation and Florida-based biopharma company Cytovia Holdings have scrapped their previously announced merger deal worth $602 million. The deal between the special ... Read More
Ipsen to acquire American biopharma company Epizyme for $247m
French pharma company Ipsen has agreed to acquire Epizyme, a Massachusetts-based commercial-stage biopharma company for an initial consideration of $247 million. Epizyme, which is listed ... Read More
Pfizer to invest $95m in French specialty vaccine company Valneva
US pharma giant Pfizer said that it will invest $95 million in Valneva, a French specialty vaccine company, for an 8.1% stake. The two firms ... Read More
BMS to acquire precision oncology company Turning Point Therapeutics for $4.1bn
Bristol Myers Squibb (BMS) has agreed to acquire Turning Point Therapeutics, a clinical-stage precision oncology company based in California, for $4.1 billion. Listed on the ... Read More
GSK to acquire vaccine developer Affinivax in deal worth up to $3.3bn
GlaxoSmithKline (GSK) has agreed to acquire Affinivax, a Boston-based clinical-stage vaccine developer, in a deal worth up to $3.3 billion. The consideration includes an upfront ... Read More
Torrent Pharma buys Styptovit-E, Finast, and other brands from Dr. Reddy’s
Torrent Pharmaceuticals has agreed to acquire the Styptovit-E, Finast, Finast-T, and Dynapress brands from Dr. Reddy's Laboratories for an undisclosed price. Styptovit-E is a gynecology ... Read More
Cullinan Oncology to sell Cullinan Pearl to Taiho Pharmaceutical for $275m
American biopharma company Cullinan Oncology has agreed to sell its subsidiary Cullinan Pearl to Taiho Pharmaceutical, a Japanese specialty pharma company, for $275 million. Cullinan ... Read More
Pfizer to acquire Biohaven in $11.6bn deal to gain access to rimegepant
Pfizer has agreed to acquire Biohaven Pharmaceutical, a US-based biopharma company, in a deal worth around $11.6 billion, to gain access to the latter’s dual-acting ... Read More